Antiobesity Drug Discovery Research: In vitro Models for Shortening the Drug Discovery Pipeline

Title:Antiobesity Drug Discovery Research: In vitro Models for Shortening the Drug Discovery Pipeline

Volume: 25 Issue: 6

Author(s): Radheshyam, Priyanka Gauniya, Mona Semalty and Ajay Semalty*

Affiliation:

• Department of Pharmaceutical Sciences, Hemwati Nandan Bahuguna Garhwal University (A Central University) Srinagar (Garhwal), Uttarakhand, India

Keywords: Pancreatic lipase inhibition, obesity and overweight, BMI, cell lines, preclinical tests, weight management, antiobesity drugs.

Abstract: Obesity is a growing global health problem, leading to various chronic diseases. Despite standard treatment options, the prevalence of obesity continues to rise, emphasizing the need for new drugs. in vitro methods of drug discovery research provide a time and cost-saving platform to identify new antiobesity drugs. The review covers various aspects of obesity and drug discovery research using in vitro models. Besides discussing causes, diagnosis, prevention, and treatment, the review focuses on the advantages and limitations of in vitro studies and exhaustively covers models based on enzymes and cell lines from different animal species and humans. In contrast to conventional in vivo animal investigations, in vitro preclinical tests using enzyme- and cell line-based assays provide several advantages in development of antiobesity drugs. These methods are quick, affordable, and provide high-throughput screening. They can also yield insightful information about drug-target interactions, modes of action, and toxicity profiles. By shedding light on the factors that lead to obesity, in vitro tests can also present a chance for personalized therapy. Technology will continue to evolve, leading to the creation of more precise and trustworthy in vitro assays, which will become more and more crucial in the search for novel antiobesity medications.

Cite this article as:

Radheshyam , Gauniya Priyanka, Semalty Mona and Semalty Ajay*, Antiobesity Drug Discovery Research: In vitro Models for Shortening the Drug Discovery Pipeline, Current Drug Targets 2024; 25 (6) . https://dx.doi.org/10.2174/0113894501289136240312060838